company background image
OMGA

Omega Therapeutics NasdaqGS:OMGA Stock Report

Last Price

US$4.56

Market Cap

US$218.2m

7D

-6.4%

1Y

-79.3%

Updated

17 Aug, 2022

Data

Company Financials +
OMGA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

OMGA Stock Overview

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company.

Omega Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Omega Therapeutics
Historical stock prices
Current Share PriceUS$4.56
52 Week HighUS$31.41
52 Week LowUS$1.98
Beta0
1 Month Change4.35%
3 Month Change64.03%
1 Year Change-79.33%
3 Year Changen/a
5 Year Changen/a
Change since IPO-71.50%

Recent News & Updates

Aug 04

Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M

Omega Therapeutics press release (NASDAQ:OMGA): Q2 GAAP EPS of -$0.54 in-line. Revenue of $0.48M beats by $0.43M. As of June 30, 2022, the company had cash, cash equivalents and marketable securities totaling $173.7M.

Jul 14

Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002

Omega Therapeutics (NASDAQ:OMGA) on Thursday said the U.S. FDA had cleared its investigational new drug (IND) application to start a phase 1/2 trial of its lead product candidate OTX-2002 for the treatment of a type of liver cancer called hepatocellular carcinoma. The company had submitted the IND to the FDA in mid-June. OMGA said the early-to-mid stage trial is expected to launch in H2 2022. The trial will evaluate the safety and preliminary antitumor activity of OTX-2002. OMGA stock fell 2.1% to $4.25 after hours.

Shareholder Returns

OMGAUS BiotechsUS Market
7D-6.4%1.8%4.5%
1Y-79.3%-22.2%-8.9%

Return vs Industry: OMGA underperformed the US Biotechs industry which returned -22.2% over the past year.

Return vs Market: OMGA underperformed the US Market which returned -8.9% over the past year.

Price Volatility

Is OMGA's price volatile compared to industry and market?
OMGA volatility
OMGA Average Weekly Movement21.6%
Biotechs Industry Average Movement12.5%
Market Average Movement7.6%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: OMGA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: OMGA's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201680Mahesh Karandehttps://www.omegatherapeutics.com

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature’s operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer.

Omega Therapeutics, Inc. Fundamentals Summary

How do Omega Therapeutics's earnings and revenue compare to its market cap?
OMGA fundamental statistics
Market CapUS$218.21m
Earnings (TTM)-US$85.46m
Revenue (TTM)US$887.00k

246.1x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OMGA income statement (TTM)
RevenueUS$887.00k
Cost of RevenueUS$60.59m
Gross Profit-US$59.70m
Other ExpensesUS$25.75m
Earnings-US$85.46m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.79
Gross Margin-6,731.00%
Net Profit Margin-9,634.50%
Debt/Equity Ratio12.6%

How did OMGA perform over the long term?

See historical performance and comparison